Biocryst Pharmaceuticals (BCRX) Shares Outstanding (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Shares Outstanding (Entity) data on file, last reported at $254.0 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 21.42% year-over-year to $254.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254.0 million (up 21.42% YoY) and the FY2025 annual result came in at $213.1 million, up 2.17% from the prior year.
• Shares Outstanding (Entity) improved to $254.0 million in Q1 2026, from $213.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $254.0 million in Q1 2026 to a low of $185.6 million in Q1 2022.
• A 5-year average of $202.7 million and a median of $206.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 781551.99% — and 2024, when it gained 1.35%.
• Tracing BCRX's Shares Outstanding (Entity) over 5 years: stood at $187.9 million in 2022, then climbed by 9.51% to $205.8 million in 2023, then gained by 1.35% to $208.5 million in 2024, then rose by 2.17% to $213.1 million in 2025, then advanced by 19.22% to $254.0 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $254.0 million (Q1 2026), $213.1 million (Q4 2025), and $210.5 million (Q3 2025), per Business Quant data.